RQM+, a Pittsburgh, PA-based global leader in MedTech services, acquired CRO Kottmann, a German contract research organization (CRO).
The amount of the deal was not disclosed.
The acquisition further supports RQM+’s strategic growth and presence in Europe. The integration of CRO Kottmann enhances RQM+’s existing geographical footprint in global operations as well as ensures comprehensive end-to-end support for clients, from pre-clinical phases to product commercialization. The addition of CRO Kottmann further expands RQM+’s business as a MedTech CRO, driving both existing and new clients’ innovations into pivotal markets.
Led by Tanja Kottmann MD, CEO, CRO Kottmann is a Contract Research Organization (CRO) that conducts clinical studies with medical devices, in vitro diagnostics (IVDs) and pharmaceuticals. In addition to full service, the company also offers individual services such as the creation of databases (eCRFs), statistical evaluations and clinical monitoring for your study.
RQM+ is a MedTech service provider offering consulting, clinical trial, lab, and reimbursement services, as well as technology solutions to support the entire product lifecycle. The company aims to reduce commercialization risk by offering a full complement of CRO services to progress medical devices, digital therapeutics and diagnostics onto the market and keep them there. In addition to early- and mid-stage MedTech companies, it currently works with 19 of the top 20 medical device manufacturers and seven of the top 10 IVD companies.
FinSMEs
30/08/2023